Ashigarakami-gun, Japan

Kentarou Furuya

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kentarou Furuya: Innovator in Pharmaceutical Chemistry

Introduction

Kentarou Furuya is a notable inventor based in Ashigarakami-gun, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on naphthyridine derivatives. His research focuses on developing compounds that can effectively inhibit critical biological pathways involved in various diseases.

Latest Patents

Kentarou Furuya holds a patent for a 1,5-naphthyridine derivative or salt thereof. This compound is represented by a specific formula where various groups can be hydrogen atoms or non-aromatic heterocyclic groups. The derivative exhibits excellent inhibitory activity concerning the PI3K-AKT pathway and the Ras-Raf-MEK-ERK pathway. This makes it particularly useful for both prophylactic and therapeutic treatments of diseases associated with these pathways.

Career Highlights

Kentarou Furuya is currently employed at Fujifilm Corporation, where he continues to advance his research in pharmaceutical innovations. His work has garnered attention for its potential applications in treating complex diseases, showcasing his expertise in the field.

Collaborations

Kentarou has collaborated with notable colleagues, including Hidetomo Furuyama and Hideki Kurihara. These partnerships have contributed to the development of innovative solutions in pharmaceutical chemistry.

Conclusion

Kentarou Furuya's contributions to the field of pharmaceutical chemistry, particularly through his patented naphthyridine derivative, highlight his role as an influential inventor. His work promises to impact the treatment of diseases significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…